The Potential for Immunogenicity of Autologous Induced Pluripotent Stem Cell-derived Therapies

Induced pluripotent stem cell (iPSC) technology offers the promise of immune-matched cell therapies for a wide range of diseases and injuries. It is generally assumed that cells derived from autologous iPSCs will be immune-privileged. However, there are reasons to question this assumption, including...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of biological chemistry 2014-02, Vol.289 (8), p.4571-4577
Main Authors: Scheiner, Zachary S., Talib, Sohel, Feigal, Ellen G.
Format: Article
Language:English
Subjects:
Animals
Cell Therapy
Cellular Immune Response
Clinical Trials as Topic
Humans
Humoral Response
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells - immunology
Induced Pluripotent Stem Cells - transplantation
Innate Immunity
iPSC
Minireviews
Stem Cell Transplantation
Transplantation, Autologous
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Induced pluripotent stem cell (iPSC) technology offers the promise of immune-matched cell therapies for a wide range of diseases and injuries. It is generally assumed that cells derived from autologous iPSCs will be immune-privileged. However, there are reasons to question this assumption, including recent studies that have tested iPSC immunogenicity in various ways with conflicting results. Understanding the risk of an immune response and developing strategies to minimize it will be important steps before clinical testing. Here, we review the evidence for autologous iPSC immunogenicity, its potential causes, and approaches for assessment and mitigation.
ISSN:0021-9258
1083-351X
DOI:10.1074/jbc.R113.509588